IRWD News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

IR

Mkt Cap

$578.3M

Volume

2.19M

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?Ironwood Pharmaceuticals (IRWD) is experiencing strong prescription demand for its primary product Linzess, with U.S. net profit share surging 72.6% year-over-year in the first half of 2026. The company raised its full-year 2026 revenue guidance to $460-$485 million, citing continued momentum from Linzess sales, recent FDA label expansion for pediatric patients, and favorable pricing dynamics. IRWD stock is trading at a valuation discount to the industry and carries a Zacks Rank #2 (Buy) rating.Zacks Investment Research · Oct 7, 2026

PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential?Precigen (PGEN) and Ironwood Pharmaceuticals (IRWD) are biotech companies heavily dependent on single marketed drugs. Precigen's Papzimeos generated $74.6 million in revenues in H1 2026 with strong growth momentum and market exclusivity until 2032, while Ironwood's Linzess saw a 72.6% year-over-year profit surge. Precigen is rated as the better investment pick with a Zacks Rank #1 (Strong Buy) versus Ironwood's Rank #2 (Buy), offering clearer long-term growth prospects despite higher valuation multiples.Zacks Investment Research · Sep 30, 2026

3 Stocks Trading Near $5 With Massive Earnings UpsideThe article identifies three penny stocks trading near $5 with significant earnings growth potential in 2026. Transocean Ltd. (RIG) is expected to grow earnings by 100% driven by favorable oil market conditions. B2Gold Corp. (BTG), a junior miner, is forecast to grow earnings by 74% as mining stocks catch up with gold prices. Ironwood Pharmaceuticals Inc. (IRWD) is projected to achieve 150% earnings growth following a 40% increase in revenue guidance, though it trades above consensus price targets.Investing.com · Feb 9, 2026

Stock Market Today: S&P 500, Nasdaq, WTI Crude Futures Advance After US Strike On Venezuela— GH Research, Vertiv Holdings, Nukkleus In Focus (UPDATED)U.S. stock futures rose on Monday as major indices opened the first full trading week of 2026 higher. Following the U.S. strike on Venezuela and removal of President Maduro, crude oil prices fluctuated around $57.29 per barrel. Several stocks gained attention: Vertiv Holdings jumped on an upgrade, GH Research soared on FDA update news, Nukkleus rose after acquiring Israeli defense software, Ironwood advanced on positive FY26 guidance, and Brand Engagement Network climbed on a new vendor agreement. JPMorgan's outlook suggests continued but challenged strength in U.S. equities, with potential 10-15% corrections offset by year-end gains driven by AI-related spending.Benzinga · Jan 5, 2026

Ironwood Finds a New Floor as LINZESS Net Pricing Turns Into a Growth LeverIronwood Pharmaceuticals shares surged 36% on January 2, 2026, after announcing 2026 financial guidance that significantly exceeded Wall Street expectations. The company expects LINZESS U.S. net sales of $1.125-1.175 billion (vs. $860-890M in 2025) and total revenue of $450-475 million (vs. consensus of $319.5M), driven by a strategic list price reduction effective January 1, 2026 that paradoxically improves net pricing by reducing statutory rebates. The stock now trades at $4.58, exceeding analyst price targets.Investing.com · Jan 2, 2026

Ironwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal DrugIronwood Pharmaceuticals' stock plunged after the FDA requested a confirmatory Phase 3 trial for its gastrointestinal drug apraglutide, despite strong data from the initial trial.Benzinga · Apr 14, 2025

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial OfficerBeam Therapeutics, a biotechnology company developing precision genetic medicines, has appointed Sravan K. Emany as its new Chief Financial Officer. Emany brings extensive experience in the life sciences industry and will help guide Beam's growth and capital allocation strategy.GlobeNewswire Inc. · Dec 6, 2024

New Strong Sell Stocks for July 5th - Zacks Investment ResearchThree stocks were added to the Zacks Rank #5 (Strong Sell) list today: Arcos Dorados Holdings Inc., Ironwood Pharmaceuticals, Inc., and Avnet, Inc. The Zacks Consensus Estimate for their current year earnings has been revised downward over the last 60 days.Zacks Investment Research · Jul 5, 2024

Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of EstimatesIronwood (IRWD) incurs loss in the first quarter of 2024. Revenues decline year over year and miss estimates. The company lowers revenue guidance for 2024. Stock falls.Zacks Investment Research · May 10, 2024

Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q1 Earnings Expected to DeclineIronwood (IRWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.Zacks Investment Research · May 2, 2024

IR

IRWDIronwood Pharmaceuticals, Inc. - Class A

IRWD

Pay with—

Available Balance0.00

Your PositionYou don't own any IRWD yet.

Related Tickers

Earnings